logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
iFluor® 790 Anti-human CD28 Antibody
9.3
The 9.3 monoclonal antibody binds with human CD28, a 44 kD transmembrane glycoprotein typically located on the surface of natural killer cells and plasma cells. CD28 is a member of vital cellular pathways, namely, the cell surface receptor signaling pathway, apoptotic signaling pathway and T cell receptor signaling pathway. Also, in some organisms, it is involved in the positive regulation of interleukin-4 production, is involved in the positive regulation of inflammatory response to antigenic stimulus and promotes isotype switching to IgG isotypes. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands such as PI3-kinase, CD86 and CD80. CD28 is a very popular antibody target, with over 30000 publications in the last decade. CD28 is vital to costimulatory molecules research, typically serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to iFluor® 790 (ex/em = 787/812 nm).
product image
product image
CatalogSize
Price
Quantity
102810M0100 tests
Price
102810M1500 tests
Price
 
Antibody properties

Other namesTp44, T44
Clone9.3
HostMouse
IsotypeMouse igg2a
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Correction factor (260 nm)0.1
Correction factor (280 nm)0.09
Extinction coefficient (cm -1 M -1)
250000
1
Excitation (nm)787
Emission (nm)812
Quantum yield
0.13
1
Storage, safety and handling

H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on January 20, 2026